TAK 935

Drug Profile

TAK 935

Alternative Names: TAK-935

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Takeda
  • Class Heterocyclic compounds; Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Steroid hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 01 Nov 2016 Takeda completes a phase-I clinical trial in Epilepsy (In volunteers) in USA (PO, Tablet) (NCT02906813)
  • 01 Oct 2016 Phase-I clinical trials in Epilepsy (In volunteers) in USA (PO, Tablet) (NCT02906813)
  • 15 Sep 2016 Takeda plans a phase I bioavailability trial in healthy volunteers in USA (PO, Tablet and Solution) (NCT02906813)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top